4.8.3Segment

Diabetes & Metabolic Devices

Manufacturers of continuous glucose monitors, insulin pumps, and metabolic disease management devices.

5
Verticals

Overview

Diabetes & Metabolic Devices covers manufacturers of continuous glucose monitors (CGMs), insulin pumps, and metabolic-disease management devices. It is one of the fastest-growing medtech categories, driven by the explosive adoption of CGMs (Dexcom, Abbott Libre) and automated insulin delivery (Insulet, Tandem, Medtronic).

CGM expansion beyond type 1 into type 2 and even non-diabetic wellness, plus the interplay with GLP-1 obesity drugs, are reshaping the category's growth. It is innovation- and consumable-driven, with recurring sensor and supply revenue, and is a high-growth focus for both strategics and investors.

Market snapshot

FragmentationConsolidatedEstimate

Within electromedical and instrument manufacturing (NAICS 334510/339112); the Census Bureau does not split out diabetes devices, so the segment is not separately sized.

Business model & economics

Revenue model

Devices plus high-margin recurring sensors and supplies

Key economics

Recurring revenue
High

recurring CGM sensors and pump supplies

EBITDA margin
Strong

recurring-consumable economics

Capex intensity
High

Characteristics

  • Among the fastest-growing medtech categories.
  • CGM adoption expanding into type 2 and wellness.
  • Recurring sensor-and-supply razor-and-blade model.

Geographic concentration

AlabamaAlaskaArizonaColoradoFloridaGeorgiaIndianaKansasMaineNew JerseyNorth CarolinaNorth DakotaOklahomaPennsylvaniaSouth DakotaTexasWyomingConnecticutMissouriWest VirginiaIllinoisNew MexicoArkansasDelawareDistrict of ColumbiaHawaiiIowaKentuckyMarylandMichiganMississippiMontanaNew HampshireNew YorkOhioOregonTennesseeVirginiaWashingtonWisconsinNebraskaSouth CarolinaIdahoNevadaVermontLouisianaRhode IslandMassachusettsMinnesotaCaliforniaUtah

Diabetes and metabolic-device manufacturing clusters in the major medtech hubs — Minnesota, Massachusetts, Utah, and California — home to the sector's leading device makers.

MinnesotaMassachusettsUtahCalifornia

U.S. Census Bureau — 2022 Statistics of U.S. Businesses (firms by state), NAICS 334510/339112. Concentration shown by location quotient.

M&A deal context

Deal activityHigh

Who’s acquiring

  • Diabetes-device strategics
  • Diversified medtech platforms
  • VC-backed innovators

What’s driving deals

  • CGM and automated-insulin-delivery growth.
  • Expansion into type 2 and metabolic wellness.
  • Recurring-consumable economics.

Verticals in this segment

Find Diabetes & Metabolic Devices acquisition targets

Search Acquisera’s index for companies classified under Diabetes & Metabolic Devices (4.8.3) and build a targeted deal pipeline.

Search companies